EP3810112A2 - Association comprenant du fingolimod et du modafinil - Google Patents
Association comprenant du fingolimod et du modafinilInfo
- Publication number
- EP3810112A2 EP3810112A2 EP19892411.0A EP19892411A EP3810112A2 EP 3810112 A2 EP3810112 A2 EP 3810112A2 EP 19892411 A EP19892411 A EP 19892411A EP 3810112 A2 EP3810112 A2 EP 3810112A2
- Authority
- EP
- European Patent Office
- Prior art keywords
- tablets
- pharmaceutical combination
- combination according
- fingolimod
- modafinil
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
Definitions
- the present invention relates to a pharmaceutical combination comprising fingolimod or a pharmaceutically acceptable salt thereof and modafinil or a pharmaceutically acceptable salt thereof for use in the treatment of multiple sclerosis in human, preferably in the prevention or the treatment of fatigue symptom of multiple sclerosis disease.
- MS Multiple Sclerosis
- CNS central nervous system
- Myelin provides a covering or insulation for nerves, improves the conduction of impulses along the nerves and also is important for maintaining the health of the nerves.
- inflammation causes the myelin to disappear. So, the electrical impulses become slower.
- the nerves themselves are damaged. Patient suffers from a range of symptoms which affect their health-related quality of life such as pain, fatigue, muscle spasticity and spasm, bladder problems and sleep disturbance.
- Fingolimod is a sphingosine-1 -phosphate receptor modulator, which sequesters lymphocytes in lymph nodes, preventing them from contributing to an autoimmune reaction. Fingolimod is used in the treatment of the relapsing form of multiple sclerosis. May also be used in chronic inflammatory demyelinating polyneuropathy.
- Fingolimod is marketed by Novartis under the brand name Gilenya® for the treatment of multiple sclerosis.
- Gilenya® is presented as immediate-release hard gelatin capsules containing 0.56 mg of fingolimod hydrochloride as the active substance corresponding to 0.5 mg of fingolimod.
- fingolimod 2-amino-2-[2-(4-octylphenyl)ethyl]propane-1 ,3-diol.
- Fingolimod is shown as Formula I.
- fingolimod derivatives are firstly disclosed in US5604229.
- the use of fingolimod derivatives as immune depressant and preventive for autoimmune diseases is disclosed in EP0627406 (B1).
- the use of fingolimod derivatives in the prevention or in the treatment of chronic rejection in a recipient of organ or tissue alio- or xeno-transplant is disclosed in EP0941082 (B1).
- MS fatigue is a common symptom of people with MS. This is called “MS fatigue” and this is different from fatigue experienced by persons without MS. This also can arise from associated conditions or accumulation of disease burden. Specific causes to consider include sleep disorders, depression, disability status.
- Modafinil is a wakefulness-promoting agent for oral administration. Modafinil is a racemic compound.
- the chemical name of modafinil is 2-[(diphenylmethyl)sulfinyl]acetamide.
- the molecular formula is C15H 15NO2S and the molecular weight is 273.35. It has the following structural formula as Formula II.
- combining more than one molecule in one dosage form increases the patient’s compliance. However, while this combination increases the patients’ quality of life, combining more than one molecule in one dosage form also reduces undesired multiple sclerosis symptoms and provide effective treatment.
- the main object of the present invention is to combine fingolimod with modafinil to eliminate multiple sclerosis symptoms and to provide effective treatment.
- Another object of the present invention is to obtain a stable combination formulation with a synergistic effect for use in multiple sclerosis.
- This invention also provides a pharmaceutical combination comprising an effective amount of fingolimod and effective amount of modafinil, for use in treating a human afflicted with multiple sclerosis.
- the combination is administered simultaneously, separately or sequentially.
- fingolimod refers to fingolimod in the form of the free base or in the form of pharmaceutically acceptable salts, crystalline polymorph, solvates, hydrates, esters or mixture thereof.
- modafinil refers to modafinil in the form of the free base or in the form of pharmaceutically acceptable salts, crystalline polymorph, solvates, hydrates, esters or mixture thereof.
- the pharmaceutical combination comprises fingolimod and modafinil.
- the combination is used as adjunctive therapy in fatigue for multiple sclerosis treatment.
- the combination is for use in the treatment of multiple sclerosis in human.
- the combination is for use to prevent or treatment fatigue symptom of MS disease.
- An embodiment of this present invention is to combine fingolimod with modafinil in a same and stable dosage form with desired dissolution profiles.
- This invention provides a method of treating a human afflicted with multiple sclerosis comprising periodical administration of an amount of fingolimod and modafinil to the subject together, wherein these amounts described below are effective to treat a human.
- the pharmaceutical combination comprises fingolimod is present in an amount of between 0.05 and 20 mg and modafinil is present in an amount of between 100 and 300 mg.
- the weight ratio of fingolimod to modafinil is between 0.0001 - 2.0, preferably 0.001 -1.0 or more preferably 0.001 - 0.2.
- said combination further comprises at least one pharmaceutically acceptable excipient which is selected from fillers, binders, disintegrants, solvents and co-solvents, rate controlling polymers, direct compression agent, surfactants, lubricants, glidants, sweeteners, stabilizers, coating agents, coloring agents or inert agents or mixtures thereof.
- at least one pharmaceutically acceptable excipient which is selected from fillers, binders, disintegrants, solvents and co-solvents, rate controlling polymers, direct compression agent, surfactants, lubricants, glidants, sweeteners, stabilizers, coating agents, coloring agents or inert agents or mixtures thereof.
- Suitable fillers are selected from the group comprising microcrystalline cellulose, mannitol, spray-dried mannitol, lactose, lactose monohydrate, starch, dextrose, sucrose, fructose, maltose, sorbitol, xylitol, inositol, kaolin, inorganic salts, calcium salts, polysaccharides, dicalcium phosphate, sodium chloride, dextrates, lactitol, maltodextrin, sucrose-maltodextrin mixture, trehalose, sodium carbonate, sodium bicarbonate, calcium carbonate or mixtures thereof.
- Suitable binders are selected from the group comprising polyvinylpyrrolidone, polyethylene glycol, polyvinyl alcohol, starch, pregelatinized starch, glucose, glucose syrup, natural gums, sucrose, sodium alginate, cellulose derivatives such as hydroxypropyl methyl cellulose, hydroxypropyl cellulose, carboxy methyl cellulose, methyl cellulose, gelatin, carrageenan, guar gum, carbomer, polymethacrylates, methacrylate polymers, collagens, proteins like gelatin, agar, alginate, alginic acid, xanthan gum, hyaluronic acid, pectin, polysaccharides, carbomer, poloxamer, polyacrylamide, aluminium hydroxide, laponite, bentonite, polyoxyethylene-alkyl ether, polydextrose, polyethylene oxide or mixtures thereof.
- Suitable disintegrants are selected from the group comprising polyvinyl pyrrolidone (crospovidone), povidone, cross-linked carboxymethyl cellulose (croscarmellose sodium), low-substituted hydroxypropyl cellulose, pregelatinized starch, sodium carboxymethyl cellulose, calcium carboxymethyl cellulose, carboxymethyl cellulose, docusate sodium, guar gum, low substituted hydroxypropyl cellulose, polyacryline potassium, sodium alginate, corn starch, sodium starch glycolate, alginic acid, alginates, ion-exchange resins, magnesium aluminium silica, sodium dodecyl sulphate, poloxamer, sodium glycine carbonate, sodium lauryl sulphate or mixtures thereof.
- polyvinyl pyrrolidone crospovidone
- povidone povidone
- carboxymethyl cellulose croscarmellose sodium
- low-substituted hydroxypropyl cellulose pregelatinized
- Suitable solvents or co-solvents are selected from the group comprising water, propylene glycol, glycerin, ethanol, polyethylene glycol or mixtures thereof.
- Suitable rate controlling polymers are selected from the group comprising ethyl acrylate, ethyl methacrylate copolymer, ethylcellulose, methylcellulose, hypromellose phthalate, polydextrose, polyvinylacetate phthalate, zein, polyvinylpyrrolidone, polyvinyl alcohol, polyvinyl acetate, hydroxypropyl cellulose, hydroxypropyl methylcellulose, hydroxyethyl cellulose, hydroxymethyl cellulose, gelatin, polyethylene oxide, acacia, dextrin, starch, polyhydroxyethylmethacrylate, sodium carboxymethylcellulose, carboxymethyl cellulose, sodium alginate, alginic acid, pectin, polyglucoronic acid, polygalacturonic acid, chondroitic sulfate, carrageenan, lambda carregeenan, iota carregeenan, furcellaran, xanthan gum, a polymer of acrylic
- Suitable direct compression agents are selected from the group comprising calcium hydrogen phosphate sodium alginate, pregelatinized starch, calcium citrate or mixtures thereof.
- Suitable surfactants are selected from the group comprising sodium docusate, glyceryl monooleate, polyethylene alkyl ether, polyoxyethylene sorbitan fatty acid ester, sodium lauryl sulfate, sorbic acid, sorbitan fatty acid ester, nonoxynol, polyoxyethylene stearates, polyethylene glycol, leucine, poloxamer 407, sodium benzoate, docusate sodium, alpha tocopherol, ascorbyl palmitate, citric acid, polyethoxylated fatty acid esters, polyoxyethylene hydrogenated castor oil or mixtures thereof.
- Suitable lubricants are selected from the group comprising from magnesium stearate, colloidal silicon dioxide, calcium stearate, zinc stearate, talc, waxes, boric acid, hydrogenated vegetable oil, sodium chlorate, magnesium lauryl sulfate, sodium oleate, sodium acetate, sodium benzoate, polyethylene glycol, stearic acid, fatty acid, fumaric acid, glyseryl palmito sulphate, sodium stearyl fumarate, sodium lauryl sulphate or mixtures thereof.
- Suitable glidants are selected from the group comprising colloidal silicon dioxide, corn starch, talc or mixtures thereof.
- Suitable sweeteners are selected from the group comprising aspartame, potassium acesulfame, sodium saccharinate, neohesperidine dihydrochalcone, sucralose, saccharin, sugars such as sucrose, glucose, lactose, fructose or sugar alcohols such as mannitol, sorbitol, xylitol, erythritol or mixtures thereof.
- Suitable stabilizers are selected from the group comprising citric acid, fumaric acid, tartaric acid, sodium citrate, sodium benzoate, sodium dihydrogen phosphate, calcium carbonate, magnesium carbonate, arginine, lysine, meglamine, ascorbic acid, gallic acid esters or the mixtures thereof, and preferably, citric acid, fumaric acid, arginine or mixtures thereof.
- Suitable coating agent are selected from the group comprising polymethacrylates, polyalkylacrylates copolymers, hydroxyl propyl methyl cellulose, lactose monohydrate, hydroxypropyl cellulose, polyvinyl alcohol, polyethylene glycol, talc, polyvinyl alcohol- polyethylene glycol copolymers (Kollicoat® IR), ethylcellulose dispersions (Surelease®), polyvinylpyrrolidone, polyvinylpyrrolidone-vinyl acetate copolymer (PVP-VA), all kinds of Opadry®, pigments, dyes, titanium dioxide, iron oxide or mixtures thereof.
- Suitable coloring agents are selected from the group comprising ferric oxide, titanium dioxide, Food, Drug & Cosmetic (FD&C) dyes (such as; FD&C blue, FD&C green, FD&C red, FD&C yellow, FD&C lakes), poncau, indigo Drug & Cosmetic (D&C) blue, indigotine FD&C blue, carmoisine indigotine (indigo Carmine); iron oxides (such as; iron oxide red, yellow, black), quinoline yellow, flaming red, carmine, carmoisine, sunset yellow or mixtures thereof.
- FD&C Food, Drug & Cosmetic
- Suitable inert agents between the two molecules are selected from starch, lactose, sugar alcohol like D-mannitol, erythritol; low-substituted hydroxypropyl cellulose, hydroxypropyl cellulose, hydroxypropyl methylcellulose, polyvinylpyrrolidone, polyvinyl alcohol, methylcellulose, hydroxyethyl methylcellulose or mixtures thereof.
- the pharmaceutical combination is administered orally.
- the pharmaceutical combination is in the form of tablets, capsules, strips, syrups, powders, pastilles, sachets, effervescent compositions, pills, coated bead systems, granules, microspheres, dragees, films, orally administrable films, solutions, solids, suspensions or emulsions.
- the pharmaceutical combination is in the form of tablets or capsules.
- the pharmaceutical combination is in the form of a tablet.
- the pharmaceutical combination is formulated as tablets comprising film- coated tablets, bilayer tablets, trilayer tablets, inlay tablets, orally disintegrating tablets, compressed tablets, coated or uncoated tablets, multilayer tablets, mini tablets, buccal tablets, sublingual tablets, effervescent tablets, gastric disintegrating tablets, chewable tablets, dispersing tablets or lozenges.
- the pharmaceutical combination is in the form of a film-coated tablet or bilayer tablet or trilayer tablet.
- the pharmaceutical combination is in the form of a capsule.
- the combination is prepared using direct compression, wet or dry granulation, hot melt granulation, hot melt extrusion, fluidized bed granulation, extrusion, spheronization, slugging, spray drying or solvent evaporation.
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Emergency Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Abstract
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
TR201808821 | 2018-06-21 | ||
PCT/TR2019/050480 WO2020117151A2 (fr) | 2018-06-21 | 2019-06-20 | Association comprenant du fingolimod et du modafinil |
Publications (2)
Publication Number | Publication Date |
---|---|
EP3810112A2 true EP3810112A2 (fr) | 2021-04-28 |
EP3810112A4 EP3810112A4 (fr) | 2022-03-16 |
Family
ID=70975010
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP19892411.0A Withdrawn EP3810112A4 (fr) | 2018-06-21 | 2019-06-20 | Association comprenant du fingolimod et du modafinil |
Country Status (2)
Country | Link |
---|---|
EP (1) | EP3810112A4 (fr) |
WO (1) | WO2020117151A2 (fr) |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2679670A1 (fr) * | 2007-03-01 | 2008-09-12 | Janssen Pharmaceutica N.V. | Composes a base d'indole et de benzothiophene en tant que modulateurs du recepteur h<sb>3</sb> de l'histamine |
EP2609912A1 (fr) * | 2011-12-30 | 2013-07-03 | Deva Holding Anonim Sirketi | Combination pharmaceutique de fingolimod et nabiximols |
GB201417165D0 (en) * | 2014-09-29 | 2014-11-12 | Provost Fellows & Scholars College Of The Holy Undivided Trinity Of Queen Elizabeth Near Dublin | Treatments for Autoimmune Disease |
EP3324975B1 (fr) * | 2015-07-22 | 2022-05-18 | John Hsu | Composition comprenant un agent thérapeutique et un stimulant respiratoire, et procédé d'utilisation associé |
DK3534904T3 (da) * | 2016-11-07 | 2022-04-11 | Metriopharm Ag | Anvendelse af 5-amino-2,3-dihydro-1,4-phthalazindion i behandlingen af kronisk progressiv multipel sklerose |
-
2019
- 2019-06-20 WO PCT/TR2019/050480 patent/WO2020117151A2/fr active Application Filing
- 2019-06-20 EP EP19892411.0A patent/EP3810112A4/fr not_active Withdrawn
Also Published As
Publication number | Publication date |
---|---|
WO2020117151A3 (fr) | 2020-08-27 |
WO2020117151A2 (fr) | 2020-06-11 |
EP3810112A4 (fr) | 2022-03-16 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CA2784819C (fr) | Utilisation de levodopa, carbidopa et entacapone en vue du traitement de la maladie de parkinson | |
US20210260006A1 (en) | Extended release dosage forms of pregabalin | |
US20080069873A1 (en) | Controlled release system and method for manufacturing the same | |
WO2008064202A2 (fr) | Formulations à libération modifiée de composés actifs vis-à-vis du récepteur de calcium | |
EP3723755A2 (fr) | Combinaisons comprenant un agent de relaxation des muscles squelettiques et un agent de traitement de la sclérose en plaques | |
EP3893866A2 (fr) | Combinaison comprenant un agent de sclérose en plaques et au moins un agent anti-épileptique | |
KR20140140353A (ko) | 안정성 및 약물상호작용이 개선된 경구용 복합 정제 조성물 | |
WO2010086868A1 (fr) | Compositions pharmaceutiques de trimétazidine | |
EP3810112A2 (fr) | Association comprenant du fingolimod et du modafinil | |
EP3810110A2 (fr) | Combinaison comprenant du fingolimod et de l'amantadine | |
AU2018278967B2 (en) | Pharmaceutical compositions of donepezil having specific in vitro dissolution profile or pharmacokinetics parameters | |
EP3810274A2 (fr) | Combinaison comprenant du fingolimod et au moins un agent anti-épileptique | |
US20200338025A1 (en) | Extended release midodrine hydrochloride compositions and methods of use | |
WO2020117161A1 (fr) | Combinaison comprenant du fumarate de diméthyle et au moins un agent de relaxation musculaire | |
EP3893855A2 (fr) | Association comprenant un agent contre la sclérose en plaques et au moins un agent relaxant musculaire | |
WO2020139238A2 (fr) | Combinaisons pharmaceutiques comprenant du fingolimod et un spasmolytique | |
TR2022010905A2 (tr) | Fampi̇ri̇di̇n ve bi̇r korti̇kosteroi̇d ajani i̇çeren bi̇r kombi̇nasyon | |
TR2021021540A2 (tr) | A combination comprising ibuprofen and at least one atypical antipsychotic agent | |
US20170189374A1 (en) | Zaltoprofen and muscle relaxant combinations | |
WO2019203748A2 (fr) | Combinaison comprenant du raloxifène et au moins un agent antipsychotique | |
WO2014132218A1 (fr) | Compositions pharmaceutiques de donépézil présentant un profil de dissolution in vitro ou des paramètres pharmacocinétiques spécifiques |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE |
|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE |
|
17P | Request for examination filed |
Effective date: 20201225 |
|
AK | Designated contracting states |
Kind code of ref document: A2 Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR |
|
AX | Request for extension of the european patent |
Extension state: BA ME |
|
DAV | Request for validation of the european patent (deleted) | ||
DAX | Request for extension of the european patent (deleted) | ||
A4 | Supplementary search report drawn up and despatched |
Effective date: 20220216 |
|
RIC1 | Information provided on ipc code assigned before grant |
Ipc: A61P 25/00 20060101ALI20220209BHEP Ipc: A61K 9/48 20060101ALI20220209BHEP Ipc: A61K 9/20 20060101ALI20220209BHEP Ipc: A61K 31/165 20060101ALI20220209BHEP Ipc: A61K 31/137 20060101AFI20220209BHEP |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN |
|
18D | Application deemed to be withdrawn |
Effective date: 20220920 |